These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25941710)

  • 1. New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful.
    Prescrire Int; 2015 Apr; 24(159):107-10. PubMed ID: 25941710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs and indications in 2013: little real progress but regulatory authorities take some positive steps.
    Prescrire Int; 2014 Apr; 23(148):107-10. PubMed ID: 24860905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data.
    Solomon C; Gröner A; Ye J; Pendrak I
    Thromb Haemost; 2015 Apr; 113(4):759-71. PubMed ID: 25502954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug safety. Why and how? "All drugs are dangerous, some are also useful"].
    Moore N
    Prog Urol; 2013 Nov; 23(15):1213-5. PubMed ID: 24183077
    [No Abstract]   [Full Text] [Related]  

  • 6. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.
    Bahri P; Dodoo AN; Edwards BD; Edwards IR; Fermont I; Hagemann U; Hartigan-Go K; Hugman B; Mol PG
    Drug Saf; 2015 Jul; 38(7):621-7. PubMed ID: 26032946
    [No Abstract]   [Full Text] [Related]  

  • 7. Encouraging spontaneous reporting of adverse effects.
    Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

  • 9. [Adverse drug reactions in children].
    Jaffan L; Läer S
    Ther Umsch; 2011 Jan; 68(1):34-40. PubMed ID: 21184392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problems encountered in the pharmacovigilance of violence and aggression.
    Prescrire Int; 2014 Jun; 23(150):154. PubMed ID: 25121149
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database.
    Fournier JP; Sommet A; Durrieu G; Poutrain JC; Lapeyre-Mestre M; Montastruc JL;
    Fundam Clin Pharmacol; 2014 Apr; 28(2):230-5. PubMed ID: 23190210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The credibility of the FDA.
    Blankfield RP
    Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacovigilance of herbal medicines.
    Gromek K; Drumond N; Simas P
    Int J Risk Saf Med; 2015; 27(2):55-65. PubMed ID: 26410008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs and indications in 2010: inadequate assessment; patients at risk.
    Prescrire Int; 2011 Apr; 20(115):105-7, 109-10. PubMed ID: 21648217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.
    Fabiano V; Mameli C; Zuccotti GV
    Expert Opin Drug Saf; 2012 Jan; 11(1):95-105. PubMed ID: 21548838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studies.
    Sato A; Narukawa M
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):770-6. PubMed ID: 25034619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.